Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cyclic guanosine monophosphate–adenosine monophosphate
- Development stage
- Preclinical
- Modality
- Small Molecules
- Administration
- Intranasal, Intraperitoneal, Intratumoral, Subcutaneous
01
Overview
Cyclic guanosine monophosphate–adenosine monophosphate (cyclic GMP-AMP or cGAMP) is an endogenous cyclic dinucleotide and second messenger that plays a pivotal role in the innate immune system. Synthesized by the cytosolic DNA sensor cyclic GMP-AMP synthase (cGAS) in response to the presence of double-stranded DNA in the cytoplasm, cGAMP binds to and activates the stimulator of interferon genes (STING) receptor. This activation triggers a downstream signaling cascade involving TANK-binding kinase 1 (TBK1) and interferon regulatory factor 3 (IRF3), leading to the production of type I interferons and other pro-inflammatory cytokines. cGAMP is widely utilized as a research reagent and is being investigated preclinically as a vaccine adjuvant and immunotherapeutic agent for infectious diseases and cancer.
- Other names
- 2',3'-cGAMP2',3'-cyclic GMP-AMP3',3'-cGAMP3',3'-cyclic GMP-AMPcGAMPcyclic GMP-AMPcyclic guanosine monophosphate-adenosine monophosphatecyclic guanosine monophosphate–adenosine monophosphate
02
Targets
IRF3 (Interferon regulatory factor 3)TBK1 (TANK binding kinase 1)Cyclic GMP–AMP synthaseSTING (Stimulator of interferon genes protein)
Beyond the preview
Go deeper on cyclic guanosine monophosphate–adenosine monophosphate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cyclic guanosine monophosphate–adenosine monophosphate.